2. GPCR/G Protein
  3. GCGR
  4. ANT308

ANT308 is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 significantly enhances the activation and proliferation of T cells. ANT308 inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. ANT308 can be used for the study of acute myeloid leukemia (AML) and uveal melanoma (UVM).

For research use only. We do not sell to patients.

ANT308

ANT308 Chemical Structure

CAS No. : 2871680-36-1

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

ANT308 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

ANT308 is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 significantly enhances the activation and proliferation of T cells. ANT308 inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. ANT308 can be used for the study of acute myeloid leukemia (AML) and uveal melanoma (UVM)[1][2].

In Vitro

ANT308 (1-10 μM, 48 h) significantly enhances CD69 and Ki67 expressions in CD4+ and CD8+ T cells[1].
ANT308 (0.1-10 μM, 72 h) reduces the viability of B16F10 and HT-144 cells dose-dependently[2].
ANT308 (10 μM, 72 h) decreases the proportion of cells in S phase, and induces apoptosis in B16LS9 and Mel 290 cells[2].
ANT308 (10 μM, 8 h) significantly inhibits cell migration in the B16LS9, Mel290, and HT-144 cell lines[2].
ANT308 (72 h) reduces MCAM and N-cadherin expression by inhibiting VIP-VPAC2 signaling[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ANT308 Related Antibodies

Cell Viability Assay[2]

Cell Line: B16F10 and HT-144 cells
Concentration: 0.1, 1, 5 and 10 μM
Incubation Time: 72 h
Result: Decreased the numbers of viable B16F10 and HT-144 cells by around 46 % and 27 %, respectively, compared to control cultures with 5 μM twice daily.

Apoptosis Analysis[2]

Cell Line: B16LS9 and Mel 290 cells
Concentration: 10 μM
Incubation Time: 72 h
Result: Increased percentages of apoptotic cells.

Cell Cycle Analysis[2]

Cell Line: B16LS9 and Mel 290 cells
Concentration: 10 μM
Incubation Time: 72 h
Result: Decreased cells in the S phase.

Cell Migration Assay [2]

Cell Line: B16LS9, B16F10, Mel 290 cells, HT-144 cells
Concentration: 10 μM
Incubation Time: 8 h
Result: Significantly inhibited cell migration in the B16LS9, Mel290, and HT-144 cell lines
In Vivo

ANT308 (6 nmol, s.c., once daily for 10-14 days) significantly prolongs the survival period of mice and reduce the tumor burden in AML model[1].
ANT308 (100 μg/100 μL PBS, s.c., twice a day for 10 days) reduces the number and size of liver metastases of mice following intraocular or subcutaneous melanoma injection, and shows a trend toward reducing tumor volume at the primary tumor site[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: P815 cells induced AML model established in DBA/2j (H2Kd) mice[1]
Dosage: 6 nmol
Administration: Subcutaneous injection (s.c.), once daily for 10-14 weeks
Result: Significantly prolonged the survival period of mice and reduced the tumor burden.
Animal Model: B16LS9 induced UVM model and B16LS9 or B16LS9 induced subcutaneous melanoma model established in female C57BL6/J mice (8-10 weeks) and NRG (NOD Rag gamma) mice (10-11 months old)[2]
Dosage: 100 μg/100 μL PBS
Administration: Subcutaneous injection (s.c.), twice a day for 10 days
Result: Significantly reduced the number of liver metastases.
Reduced MCAM, but had no significant effect on N-cadherin expression.
had no significant effect on subcutaneous tumor volume.
Molecular Weight

3467.10

Formula

C156H261N47O40S
CAS No.
Sequence

Lys-Pro-Arg-Arg-Pro-Tyr-Thr-Ser-Asp-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Leu-Ile-Leu-Asn
Sequence Shortening

KPRRPYTSDYTRLRKQMAVKKYLNLILN
SMILES

O=C(N1[C@@H](CCC1)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N2[C@@H](CCC2)C(N[C@@H](CC3=CC=C(C=C3)O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(N[C@@H](CC4=CC=C(C=C4)O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCSC)C(N[C@@H](C)C(N[C@@H](C(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CC5=CC=C(C=C5)O)C(N[C@@H](CC(C)C)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(C)C)C(N[C@@H](CC(N)=O)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCCCN)N
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

ANT308 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

ANT3082871680-36-1ANT 308ANT-308GCGRGlucagon ReceptorVIPPEGylationpeptide stapleacute myeloid leukemiaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
ANT308
Cat. No.:
HY-P11288
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.